Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy?

References

• Kucukyurt S, Eskazan AE. Assessment and monitoring of patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP): strategies to improve outcomes. J Blood Med. 2020;11:319-326.
   Google Scholar
• Goel R, Ness PM, Takemoto CM, et al. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood. 2015;125(9):1470–1476.
   PubMed Web of Science ®Google Scholar
• Elverdi T, Eskazan AE. Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura. Drug Des Devel Ther. 2019;13:1251–1258.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016;374(6):511–522.
   PubMed Web of Science ®Google Scholar
• Coppo P, Bubenheim M, Azoulay E, et al. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood. 2021;137(6):733–742.
   PubMedGoogle Scholar
• Dutt T, Shaw RJ, Stubbs MJ, et al. Real-world evidence of caplacizumab use in the management of acute TTP. Blood. 2021;137(13):1731-1740.
   Google Scholar
• Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2017;15(7):1448–1452.
   PubMed Web of Science ®Google Scholar
• Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335–346.
   PubMed Web of Science ®Google Scholar
• Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020 Oct;18(10):2496–2502.
   PubMed Web of Science ®Google Scholar
• Picod A, Veyradier A, Coppo P. Should all patients with immune‐mediated thrombotic thrombocytopenic purpura receive caplacizumab? J Thromb Haemost. 2021;19(1):58–67.
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Sauvètre G, Grangé S, et al. Venous thrombo-embolism during immune-mediated thrombotic thrombocytopenic purpura is prevalent in patients with a prolonged treatment with therapeutic plasma exchange. Rev Med Internet. 2020;41(12):809–813.
   PubMed Web of Science ®Google Scholar
• Rizvi M, Vesely S, George J, et al. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura‐hemolytic‐uremic syndrome. Transfusion. 2000;40(8):896–901.
   PubMed Web of Science ®Google Scholar
• Tse B, Lim G, Sholzberg M, et al. Describing the point prevalence and characteristics of venous thromboembolism in patients with thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18(11):2870-2877.
   Google Scholar
• Yarranton H, Cohen H, Pavord SR, et al. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol. 2003;121(5):778–785.
   PubMed Web of Science ®Google Scholar
• Quintini G, Barbera V, Iannitto E, et al. Continuous intravenous infusion of dipyridamole as adjunctive therapy in the treatment of thrombotic thrombocytopenic purpura. Transfus Apheresis Sci. 2003;29(2):141–145.
   PubMed Web of Science ®Google Scholar
• Bobbio-Pallavicini E, Gugliotta L, Centurioni R, et al. Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP. Haematologica. 1997;82(4):429–435.
   PubMed Web of Science ®Google Scholar
• Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med. 1991;325(6):393–397.
   PubMed Web of Science ®Google Scholar
• Rosove MH, Ho WG, Goldfinger D. Ineffectiveness of aspirin and dipyridamole in the treatment of thrombotic thrombocytopenic purpura. Ann Intern Med. 1982;96(1):27–33.
   PubMed Web of Science ®Google Scholar
• Völker LA, Kaufeld J, Miesbach W, et al. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood Adv. 2020;4(13):3085–3092.
   PubMed Web of Science ®Google Scholar
• Knoebl P, Cataland S, Peyvandi F, et al. Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. J Thromb Haemost. 2020;18(2):479–484.
   PubMed Web of Science ®Google Scholar
• Kremer Hovinga JA, Scully M, Cataland SR, et al. Safety of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura - results normalized to time of exposure in a double-blind, placebo-controlled, phase 3 hercules study. Blood. 2018;132(Supplement 1): 3744-3744.
   Google Scholar
• Cilla N, Dallemagne J, Vanhove M, et al. Delayed thrombotic complications in a thrombotic thrombocytopenic purpura patient treated with caplacizumab. J Hematol. 2020;9(3):84.
   PubMedGoogle Scholar
• Matsumoto M, Fujimura Y, Wada H, et al. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan. Int J Hematol. 2017 Jul;106(1):3–15.
   PubMed Web of Science ®Google Scholar
• Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158(3):323–335.
   PubMed Web of Science ®Google Scholar
• Zheng XL, Vesely SK, Cataland SR, et al. Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18(10):2503–2512.
   PubMed Web of Science ®Google Scholar
• Sargentini-Maier ML, De Decker P, Tersteeg C, et al. Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura. Expert Rev Clin Pharmacol. 2019;12(6):537–545.
   PubMed Web of Science ®Google Scholar